A 45-year-old man who had received his second mRNA COVID-19 vaccination one week earlier was presented to the emergency department with chest discomfort. Therefore, we suspected post-vaccination myocarditis; however, the patient showed no signs of myocarditis. After 2 weeks, he revisited the hospital complaining of palpitations, hand tremors, and weight loss. The patient exhibited high free thyroxine (FT4) (6.42 ng/dL), low thyroid-stimulating hormone (TSH) (<0.01 μIU/mL), and high TSH receptor antibody (17.5 IU/L) levels, and was diagnosed with Graves' disease. Thiamazole was administered, and the patient's FT4 levels normalized after 30 days. One year later, the patient's FT4 is stable; however, their TSH receptor antibodies have not become negative and thiamazole has continued. This is the first case report to follow the course of Graves' disease one year after mRNA COVID-19 vaccination.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222727PMC
http://dx.doi.org/10.3390/vaccines11050934DOI Listing

Publication Analysis

Top Keywords

mrna covid-19
8
covid-19 vaccination
8
graves' disease
4
disease mrna
4
vaccination presence
4
presence autoimmune
4
autoimmune antibodies
4
antibodies year
4
year 45-year-old
4
45-year-old man
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!